ChromaDex (CDXC)
(Delayed Data from NSDQ)
$3.19 USD
-0.01 (-0.31%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $3.18 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CDXC 3.19 -0.01(-0.31%)
Will CDXC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CDXC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDXC
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
CDXC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Other News for CDXC
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
ChromaDex launches Niagen+ NAD+ Test Kit available exclusively to HCPs
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
ChromaDex announces appointment of Carlos Lopez as General Counsel